The Food and Drug Administration on Friday approved a new medication for premenopausal women whose flagging libidos are a source of personal distress or relationship difficulties. The condition, which was first recognized in its gender-specific form in , is thought to affect as many as 1 in 10 women before the onset of menopause, and many more after that. Hylton V. Based on a compound first explored as a tanning product, Vyleesi activates melanocortin receptors, which modulate skin tone. Nicole H.
The U. Food and Drug Administration today approved Vyleesi bremelanotide to treat acquired, generalized hypoactive sexual desire disorder HSDD in premenopausal women. Joffe, M. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. Acquired HSDD develops in a patient who previously experienced no problems with sexual desire. Vyleesi activates melanocortin receptors, but the mechanism by which it improves sexual desire and related distress is unknown.
We respect your privacy. However, if your disinterest is causing distress in your life, then you may be diagnosed with hypoactive sexual desire disorder HSDD. An estimated 30 to 39 percent of women in any given population will report little or no interest in sex at any given time in their lives. This may not cause personal problems or constitute a sex disorder, especially if the woman is single and not actively engaged with a partner.
Cindy Meston, Ph. Sexual interest refers to the motivation to engage in sexual activity. Sexual arousal is conceptualized as the second phase of the sexual response cycle and defined by both physical and mental readiness for sexual activity. Physiological changes occur in the body to prepare for a sexual interaction erection in males, vaginal swelling and lubrication in females.